Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: A report from the DIGAMI 2 trial

Diabetes Care

Volumn 33, Issue 7, 2010, Pages 1604-1606

  Mellbin, Linda G ^a   Rydén, Lars ^a   Brismar, Kerstin ^a   Morgenthaler, Nils G ^b   Öhrvik, John ^a   Catrina, Sergiu B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Research Department   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG; VASOPRESSIN; COPEPTINS; GLYCOPEPTIDE; IGFBP1 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; AGE; ARTICLE; COHORT ANALYSIS; CORRELATION COEFFICIENT; FOLLOW UP; HAZARD RATIO; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STROKE; SUDDEN DEATH; UNIVARIATE ANALYSIS; AGED; BLOOD; FEMALE; HEART INFARCTION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; PROGNATHIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; DEATH, SUDDEN, CARDIAC; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNATHISM; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 77958179768     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0088     Document Type: Article

References (15)

1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-119
2. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-49
3. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vas- culature in health and in septic shock. Crit Care Med 2007;35:33-40
4. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-2110 (Pubitemid 46659061)
5. Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997;216:319-357
6. Wallander M, Norhammar A, Malmberg K, Öhrvik J, Rydén L, Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 2007;30:2343-2348
7. Catrina SB, Rotarus R, Botusan IR, Coculescu M, Brismar K. Desmopressin increases IGF-binding protein-1 in humans. Eur J Endocrinol 2008;158:479-482
8. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A, DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-661
9. Póvoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 1984;107:563-570
10. Goldsmith SR. Treatment options for hyponatremia in heart failure. Heart Fail Rev 2009;14:65-73
11. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009;20:153-162
12. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994;79:872-878
13. Mesotten D, Van den Berghe G: Changes within the GH/IGF-I/IGFBP axis in critical illness. Crit Care Clin 2006;22:17-28
14. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH, Jr, Kullo IJ. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558-2564
15. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144